Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28349495 | 0.89 | HDAC6 (0.65) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL28349497 | 0.89 | HDAC6 (0.65) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL29406239 | 0.89 | HDAC6 (0.76) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL229510 | 0.89 | HDAC6 (0.76) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL28353684 | 0.88 | HDAC6 (0.64) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL28353686 | 0.88 | HDAC6 (0.64) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL2019945 | 0.88 | HDAC6 (0.74) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL2781680 | 0.88 | HDAC6 (0.74) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL14823504 | 0.87 | HDAC6 (0.73) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL2171472 | 0.86 | HDAC6 (0.79) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113530-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210008035-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200368355-A1 | FORMULATIONS OF BENDAMUSTINE | EAGLE PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20190151234-A1 | STABLE LIQUID PHARMACEUTICAL FORMULATIONS OF BENDAMUSTINE | LEIUTIS PHARMACEUTICALS PVT. LTD. (IN) | 2019-05-23 | — | — | US | disclosed |
| US-20180185488-A1 | FORMULATIONS OF BENDAMUSTINE | EAGLE PHARMACEUTICALS INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185488-A1 | FORMULATIONS OF BENDAMUSTINE | EAGLE PHARMACEUTICALS INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180125824-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | DRAGER ANTHONY S (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180125824-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | DRAGER ANTHONY S (US) | 2018-05-10 | — | — | US | disclosed |
| US-9643932-B2 | Process for the preparation of bendamustine hydrochloride | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-9643932-B2 | Process for the preparation of bendamustine hydrochloride | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20140080881-A1 | Liquid Formulations of Bendamustine | CEPHALON, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080881-A1 | Liquid Formulations of Bendamustine | CEPHALON, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130041004-A1 | Liquid Formulations Of Bendamustine | DRAGER ANTHONY S (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130041004-A1 | Liquid Formulations Of Bendamustine | DRAGER ANTHONY S (US) | 2013-02-14 | — | — | US | disclosed |
| US-8344006-B2 | Liquid formulations of bendamustine | CEPHALON, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344006-B2 | Liquid formulations of bendamustine | CEPHALON, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120129904-A1 | Liquid Formulations Of Bendamustine | CEPHALON, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129904-A1 | Liquid Formulations Of Bendamustine | CEPHALON, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20110190363-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190363-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080881-A1 | Liquid Formulations of Bendamustine | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
| US-20120129904-A1 | Liquid Formulations Of Bendamustine | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
| US-20200368355-A1 | FORMULATIONS OF BENDAMUSTINE | FOLR2, BHMT, THPO | HDAC6 1523/4885HDAC1 3710/4885HDAC3 3836/4885 |
| US-20180185488-A1 | FORMULATIONS OF BENDAMUSTINE | FOLR2, BHMT, THPO | HDAC6 1523/4885HDAC1 3710/4885HDAC3 3836/4885 |
| US-20210113530-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
| US-20190151234-A1 | STABLE LIQUID PHARMACEUTICAL FORMULATIONS OF BENDAMUSTINE | SPHK2, THPO, SPHK1 | HDAC6 937/4885HDAC1 1646/4885HDAC3 2356/4885 |
| US-20130041004-A1 | Liquid Formulations Of Bendamustine | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
| US-20180125824-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
| US-20210008035-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
| US-20110190363-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.